Top-Rated StocksTop-RatedNASDAQ:ACLX Arcellx (ACLX) Stock Price, News & Analysis $65.21 -0.33 (-0.50%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$64.11 -1.10 (-1.69%) As of 08:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcellx Stock (NASDAQ:ACLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcellx alerts:Sign Up Key Stats Today's Range$62.74▼$65.9550-Day Range$52.77▼$72.4852-Week Range$47.86▼$107.37Volume1.62 million shsAverage Volume596,594 shsMarket Capitalization$3.59 billionP/E RatioN/ADividend YieldN/APrice Target$111.33Consensus RatingBuy Company OverviewArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Read More… Arcellx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreACLX MarketRank™: Arcellx scored higher than 32% of companies evaluated by MarketBeat, and ranked 723rd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArcellx has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcellx has only been the subject of 1 research reports in the past 90 days.Read more about Arcellx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcellx are expected to decrease in the coming year, from ($1.58) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcellx is -91.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcellx is -91.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcellx has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.92% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcellx does not currently pay a dividend.Dividend GrowthArcellx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.92% of the float of Arcellx has been sold short.Short Interest Ratio / Days to CoverArcellx has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous month News and Social Media2.7 / 5News Sentiment0.77 News SentimentArcellx has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Arcellx this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ACLX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows4 people have added Arcellx to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcellx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,495,548.00 in company stock.Percentage Held by InsidersOnly 6.24% of the stock of Arcellx is held by insiders.Percentage Held by Institutions96.03% of the stock of Arcellx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcellx's insider trading history. Receive ACLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter. Email Address ACLX Stock News HeadlinesArcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025May 21 at 4:19 PM | businesswire.comBaron Discovery Fund Initiated a Position in Arcellx (ACLX)May 20 at 11:54 AM | finance.yahoo.comWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.May 23, 2025 | Priority Gold (Ad)Scotiabank Reaffirms Their Buy Rating on Arcellx Inc (ACLX)May 18, 2025 | theglobeandmail.comArcellx Inc (ACLX) Receives a Buy from Canaccord GenuityMay 18, 2025 | theglobeandmail.comFY2025 EPS Estimates for Arcellx Cut by Cantor FitzgeraldMay 15, 2025 | americanbankingnews.comArcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple MyelomaMay 14, 2025 | businesswire.comHere’s Why Arcellx (ACLX) Declined in Q1May 12, 2025 | msn.comSee More Headlines ACLX Stock Analysis - Frequently Asked Questions How have ACLX shares performed this year? Arcellx's stock was trading at $76.69 on January 1st, 2025. Since then, ACLX stock has decreased by 15.0% and is now trading at $65.21. View the best growth stocks for 2025 here. How were Arcellx's earnings last quarter? Arcellx, Inc. (NASDAQ:ACLX) released its quarterly earnings results on Thursday, May, 8th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.29. The company earned $8.13 million during the quarter, compared to analyst estimates of $19.51 million. Arcellx had a negative trailing twelve-month return on equity of 8.28% and a negative net margin of 25.94%. When did Arcellx IPO? Arcellx (ACLX) raised $132 million in an initial public offering on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share. Who are Arcellx's major shareholders? Top institutional shareholders of Arcellx include Paradigm Biocapital Advisors LP (8.16%), Vanguard Group Inc. (7.24%), RA Capital Management L.P. (5.51%) and Vestal Point Capital LP (4.34%). Insiders that own company stock include Enterprise Associates 15 New, Sr One Capital Management, Llc, Jill Carroll, Rami Elghandour, Christopher Heery, Michelle Gilson, Olivia C Ware, Olivia C Ware and Kavita Patel. View institutional ownership trends. How do I buy shares of Arcellx? Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcellx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcellx investors own include Humana (HUM), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), American Water Works (AWK), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/08/2025Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACLX CIK1786205 Webarcellx.com Phone240-327-0603FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$111.33 High Stock Price Target$136.00 Low Stock Price Target$93.00 Potential Upside/Downside+70.7%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,690,000.00 Net Margins-25.94% Pretax Margin-25.18% Return on Equity-8.28% Return on Assets-5.21% Debt Debt-to-Equity RatioN/A Current Ratio4.29 Quick Ratio4.29 Sales & Book Value Annual Sales$76.81 million Price / Sales46.79 Cash FlowN/A Price / Cash FlowN/A Book Value$9.97 per share Price / Book6.54Miscellaneous Outstanding Shares55,107,000Free Float50,701,000Market Cap$3.59 billion OptionableOptionable Beta0.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ACLX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcellx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcellx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.